MedTrace Logo

Generative AI-Based Simulation for Diagnostic Communication in Type 2 Diabetes (DIALOGUE-DM2)

NCT07252193 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-12-29

No results posted yet for this study

Summary

This randomized controlled trial evaluates the effectiveness of a generative artificial intelligence (AI)-based simulation program in improving diagnostic communication skills among medical students. The study is conducted at the Faculty of Higher Studies Iztacala, National Autonomous University of Mexico (UNAM).

A total of 120 medical students are randomized to either an intervention group using the DIALOGUE-DM2 AI simulation platform or a control group following traditional educational methods. Participants complete a pre-test, receive training according to group assignment, and then undergo a post-test evaluation.

The primary outcome is improvement in diagnostic communication skills, measured by standardized patient scenarios and validated rubrics. Secondary outcomes include self-reported confidence, communication domains, and inter-rater agreement between faculty evaluators and AI scoring.

This trial aims to provide high-quality evidence on the potential of generative AI to enhance communication training in medical education, specifically in the context of type 2 diabetes diagnosis.

Conditions

Interventions

BEHAVIORAL

AI-Based Simulation Training (DIALOGUE-DM2)

Medical students interact with the DIALOGUE-DM2 platform, a generative AI-based simulation system. The platform delivers virtual patient encounters focused on type 2 diabetes diagnostic disclosure. Students complete multiple simulated scenarios and receive immediate AI-generated feedback aligned with standardized communication rubrics (Kalamazoo, MRS). Training aims to enhance diagnostic communication skills prior to post-test evaluation.

BEHAVIORAL

Traditional Training

Medical students receive traditional training in diagnostic communication. This includes lectures, peer role-play, and faculty-supervised feedback sessions covering diagnostic disclosure in type 2 diabetes. The training duration and number of sessions are matched to the intervention group.

Sponsors & Collaborators

  • Universidad Nacional Autonoma de Mexico

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
29 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-22
Primary Completion
2025-12-18
Completion
2025-12-20

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07252193 on ClinicalTrials.gov